WVE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

17.12M

-79.56%

-0.242

-189.57%

7.17M

-21.8%

-0.310

+6.8%

8.17M

-6.03%

-0.315

+1.73%

Estimates Revision

The market is revising No Change the revenue expectations for Wave Life Sciences Ltd. (WVE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 82.11%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+82.11%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is 18.09 USD with a low forecast of 9.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

18.09

High

26.00

Current: 0.000

Low

9.00

Averages

18.09

High

26.00

H.C. Wainwright

Andrew Fein

Buy

upgrade

$22 -> $30

2025-12-19

Reason

H.C. Wainwright

Andrew Fein

Price Target

$22 -> $30

2025-12-19

upgrade

Buy

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on Wave Life Sciences to $30 from $22 and keeps a Buy rating on the shares. The firm says its key opinion leader validation and dose-response modeling confirm WVE-007 as a potential "body recomposition" agent, delivering 9.4% visceral fat loss and 3.2% lean mass gain with zero GI issues. Experts identify a significant unmet need for this profile as both a "maintenance" offramp and a synergistic add-on to GLP-1s, uniquely solving the issues of visceral adiposity, muscle loss, and weight rebound, Wainwright adds. The firm's modeling indicates that higher doses will accelerate fat loss to competitive levels, while the clean safety profile clears the path for a differentiated commercial label. Wainwright views upcoming competitor readouts not as threats, but as class validation, positioning Wave to own the "quality" weight loss vertical.

Oppenheimer

Outperform

maintain

$24 -> $32

2025-12-16

Reason

Oppenheimer

Price Target

$24 -> $32

2025-12-16

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Wave Life Sciences to $32 from $24 and keeps an Outperform rating on the shares following the interim results for WVE-007 and the follow-through last week. To the firm, the most important takeaways from the highly encouraging update are the clean safety profile and the clear translatability from human genetics and preclinical work to clinical results for WVE-007. Oppenheimer is optimistic that the data will further improve with longer follow-up/higher doses, and in subsequent studies.

Truist

Buy

maintain

$36 -> $50

2025-12-15

Reason

Truist

Price Target

$36 -> $50

2025-12-15

maintain

Buy

Reason

Truist raised the firm's price target on Wave Life Sciences to $50 from $36 and keeps a Buy rating on the shares. The firm's obesity model for WVE-007 is a "conservative placeholder" as it tracks maturing data that may fundamentally shift the conversation from "weight loss" to "quality weight loss" that could drive greater utilization of WVE-007 at higher premium if successfully developed, the analyst tells investors in a research note. Truist expects competition but also views Wave Life Sciences' stereopure siRNA platform with innovative backbone chemistry as has having a strong moat that has now been validated through four consecutive successful data readouts, the firm added.

B. Riley

Buy

upgrade

$19 -> $37

2025-12-12

Reason

B. Riley

Price Target

$19 -> $37

2025-12-12

upgrade

Buy

Reason

B. Riley raised the firm's price target on Wave Life Sciences to $37 from $19 and keeps a Buy rating on the shares reflecting strategic value and projected obesity-related revenues. Despite minimal absolute weight loss at the low dose of WVE-007, preclinical modeling suggests continued efficacy, and upcoming obesity and RNA-editing catalysts are expected to provide tailwinds through 2026, the analyst tells investors in a research note.

Wedbush

Yun Zhong

Outperform

upgrade

$20 -> $33

2025-12-12

Reason

Wedbush

Yun Zhong

Price Target

$20 -> $33

2025-12-12

upgrade

Outperform

Reason

As previously reported, Wedbush analyst Yun Zhong added Outperform-rated Wave Life Sciences to the firm's Best Ideas List and raised the price target on the stock to $33 from $20 following the positive initial WVE-007 Phase 1 data in obesity. Additional data from higher dose cohorts in Q1 and Q2 2026 could show further improved weight reduction with good muscle preservation, and the WVE-006 clinical update in alpha-1 antitrypsin deficiency in Q1 2026 and NDA submission for WVE-N531 in Duchenne muscular dystrophy should provide additional catalysts, Wedbush argues.

Wedbush

Outperform

upgrade

$20 -> $33

2025-12-12

Reason

Wedbush

Price Target

$20 -> $33

2025-12-12

upgrade

Outperform

Reason

Wedbush added Outperform-rated Wave Life Sciences to the firm's Best Ideas List and raised the price target on the stock to $33 from $20 and keeps an Outperform rating on the shares. The firm believes this is "just the beginning of the next wave."

Valuation Metrics

The current forward P/E ratio for WAVE Life Sciences Ltd (WVE.O) is -13.08, compared to its 5-year average forward P/E of -5.17. For a more detailed relative valuation and DCF analysis to assess WAVE Life Sciences Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.17

Current PE

-13.08

Overvalued PE

-1.83

Undervalued PE

-8.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.57

Current EV/EBITDA

-13.49

Overvalued EV/EBITDA

0.97

Undervalued EV/EBITDA

-6.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

14.84

Current PS

71.28

Overvalued PS

26.51

Undervalued PS

3.17

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

WVE News & Events

Events Timeline

No data

News

9.0

01-06Barron's

Arrowhead Drug Enhances Eli Lilly's Zepbound Weight Loss Results in Initial Trial

4.0

01-05NASDAQ.COM

IHE ETF Shows 9.94% Upside Potential Based on Analyst Targets

6.5

2025-12-18MarketWatch

Insights on On-Device AI and the 'Girlfriend Index': Investment Ideas from the Research Firm That Predicted 2025's Trends

People Also Watch

Frequently Asked Questions

What is WAVE Life Sciences Ltd (WVE) stock price today?

The current price of WVE is 13.84 USD — it has decreased -6.68 % in the last trading day.

What is WAVE Life Sciences Ltd (WVE)'s business?

Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).

What is the price predicton of WVE Stock?

What is WAVE Life Sciences Ltd (WVE)'s revenue for the last quarter?

WAVE Life Sciences Ltd revenue for the last quarter amounts to 7.61M USD, decreased -199.11 % YoY.

What is WAVE Life Sciences Ltd (WVE)'s earnings per share (EPS) for the last quarter?

WAVE Life Sciences Ltd. EPS for the last quarter amounts to -0.32 USD, decreased -31.91 % YoY.

What changes have occurred in the market's expectations for WAVE Life Sciences Ltd (WVE)'s fundamentals?

How many employees does WAVE Life Sciences Ltd (WVE). have?

WAVE Life Sciences Ltd (WVE) has 287 emplpoyees as of January 10 2026.

What is WAVE Life Sciences Ltd (WVE) market cap?

Today WVE has the market capitalization of 2.57B USD.